RxDoctor Payments Data

Naomi Salins, MD

Neurology · Phoenix, AZNPI 1316263411

Payments from drug & device makers

$1,549in general payments, 2019–2025

Across 15 payments — averaging $103.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$650
  • Medtronic$520
  • Teva Pharmaceuticals USA, Inc.$203
  • MDD US Operations, LLC$72
  • UCB, Inc.$63
  • Abbott$40
  • plus $1 from 1 others

What the payments were for

  • Consulting fees$1,17076%
  • Food & beverage$17511%
  • Education$20413%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,549 in reported general payments places this provider in the 40th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$729,475
Medicare patients
331
Services billed
78,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate133$689,450
IngrezzaValbenazine Tosylate64$513,941
AustedoDeutetrabenazine26$351,974
RytaryCarbidopa/Levodopa211$344,497
GocovriAmantadine Hcl50$162,835
BotoxOnabotulinumtoxina23$63,957
Carbidopa-LevodopaCarbidopa/Levodopa631$27,504
NeuproRotigotine21$23,088
Carbidopa-Levodopa ErCarbidopa/Levodopa377$21,126
Rasagiline Mesylate95$20,377
Entacapone97$14,124
Rivastigmine57$9,726
AmantadineAmantadine Hcl160$7,908
Gabapentin185$2,696
Clonazepam244$2,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$203$351,97426 claims
MDD US Operations, LLCGocovri$72$162,83550 claims
AbbVieBotox$650$63,95723 claims
UCB, Inc.Neupro$63$23,08821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 388 neurology providers in Arizona.

Other neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →